Menopause associated with increased prevalence of cardiovascular autonomic neuropathy in women with diabetes: this study

Published Date: 02 Mar 2023

Spain: A recent study showed an increase in subclinical autonomic neuropathy (CAN) in women aged 1...

Read Full News

Latest News

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Icodec-Semaglutide Combo Outperforms Glargine in T2D Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Latest News

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

News All Time

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System Ryan Livingston

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD Rajiv Agarwal, MD, MS

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Survey Shows Peptide Misinformation, Misuse Rising in US Ashish Rana, MD

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D Ryan Livingston

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Recommended News For You

Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

Slowdown in progress found with cancer survival in England and Wales

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Recommended Articles For You

Immune Regulation of Megakaryocyte Development 

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition 

How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases? 

3D Molecular Tumor Mapping for Therapy Selection 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

3.

Beyond What Is Visible in Myelofibrosis?

4.

Dual imaging capsule captures 3D tissue and blood vessel changes for early esophageal cancer diagnosis

5.

FDA Approves Hemophilia B Second Gene Therapy.

1.

Oncology in High-Risk Populations: Prevention, Screening and Early Detection in Hereditary and Sex-Specific Cancers

2.

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options

3.

Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction

4.

AI Detection of Abnormal Platelet Morphology: Clinical Applications and Scientific Advances

5.

Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

2.

Understanding Anemia: Causes and Treatment

3.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

4.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot